Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy [Phase 4]
Phase 4 trial evaluating how anti-epileptic drugs influence the pharmacokinetics of the etonogestrel-releasing implant in women with epileps…
-
FDA approval · 2025-01-27FDA Approved: ACETAZOLAMIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for Acetazolamide from Accord Healthcare Inc. under an Abbreviated New Drug Application.
-
FDA approval · 2025-01-27FDA Approved: CARBAMAZEPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Carbamazepine from Torrent Pharmaceuticals Limited under an ANDA.
-
CLINICAL_TRIALS research · 2025-01-27Clinical Trial Update: Efficacy of taVNS Versus Sham Stimulation in Reduing Depressive Symptoms in Patients With Epilepsy: a Multi-center, Double-blinded, Randomized, 20-week, Parallel-arm, Superiority Study [NA]
A multi-center, double-blind trial compares taVNS to sham to evaluate reduction of depressive symptoms in patients with epilepsy over 20 wee…
-
FDA approval · 2025-01-23FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: Structural and Functional Connectivity in Partial Epilepsies Studied with MRI and MEG
This ClinicalTrials.gov entry documents a completed study investigating structural and functional brain connectivity in partial epilepsies u…
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: BOTOX Effects on Seizure Severity and Susceptibility [Phase 4]
A Phase 4 trial evaluating Botox (onabotulinumtoxinA) for effects on seizure severity and susceptibility in drug-resistant focal seizures wa…
-
CLINICAL_TRIALS research · 2025-01-22Clinical Trial Update: Evaluating Modulation Effects of Burst Stimulation Patterns Using SEEG [NA]
Ongoing clinical trial at Xuanwu Hospital in Beijing evaluating how burst stimulation patterns modulate brain activity in epilepsy using SEE…
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: The Effectiveness and Safety of Resective Epilepsy Surgery for TRE
This clinical trial update reports on the effectiveness and safety of resective epilepsy surgery for tuberous sclerosis complex–related epil…
-
CLINICAL_TRIALS research · 2025-01-17Clinical Trial Update: Neuropsychiatric Research Databases for People With Intellectual Disabilities and Epilepsy (REFINE)
This clinical trial update describes the REFINE study, a University of Plymouth-led effort to develop neuropsychiatric research databases fo…
-
CLINICAL_TRIALS research · 2025-01-16Clinical Trial Update: Transition From Pediatric to Adult Epilepsy Care
This clinical trial update notes a transition plan from pediatric to adult epilepsy care and indicates the study is currently recruiting.
-
FDA approval · 2025-01-16FDA Approved: LEVETIRACETAM — Original Application (Somerset Therapeutics, LLC)
FDA approved Somerset Therapeutics, LLC's original abbreviated new drug application for levetiracetam in sodium chloride, a generic formulat…
-
CLINICAL_TRIALS research · 2025-01-15Clinical Trial Update: Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
This update describes a study on re-using clinical trial data with tailored statistical methods for rare diseases. The focus includes tubero…
-
FDA approval · 2025-01-14FDA Approved: CARBAMAZEPINE — Supplemental Application (Ingenus Pharmaceuticals, LLC)
FDA approved a supplemental application for a generic Carbamazepine product from Ingenus Pharmaceuticals, LLC.
-
FDA approval · 2025-01-14FDA Approved: CARBAMAZEPINE — Original Application (Ascend Laboratories, LLC)
FDA approved a generic carbamazepine product from Ascend Laboratories, LLC under an Original Application (ANDA).
-
FDA approval · 2025-01-13FDA Approved: CARBAMAZEPINE — Original Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's original application for a generic carbamazepine product.
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: Novel Helmet Design in Patients With Seizures [NA]
A completed clinical trial update reports results for a novel helmet design intended to assist people with epilepsy and seizure-related inci…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder [NA]
A clinical trial update indicates recruitment is ongoing for a study on neurobehavioral therapy to treat adults with epilepsy and major depr…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age
This clinical trial update outlines a study on genotype, phenotype, and disease progression of developmental epileptic encephalopathy that b…
-
EMA withdrawal · 2025-01-09EMA Application withdrawn: Epixram — Neuraxpharm Pharmaceuticals S.L.
The European Medicines Agency has withdrawn the marketing authorization application for Epixram by Neuraxpharm Pharmaceuticals S.L., related…
-
FDA approval · 2025-01-08FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lamotrigine from Zydus Pharmaceuticals USA Inc. under an ANDA, indicating an approved change…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions [Phase 1]
Phase 1 bioequivalence study evaluating two brivaracetam oral solutions in healthy adults under fasting and high-fat meal conditions.
-
FDA approval · 2024-12-31FDA Approved: GABAPENTIN — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
FDA approved a supplemental application for gabapentin by ScieGen Pharmaceuticals, Inc.
-
FDA label_change · 2024-12-31FDA Approved: GABAPENTIN — Supplemental Application (Laurus Labs Limited)
FDA approved a supplemental application for gabapentin filed by Laurus Labs Limited, indicating a post-approval labeling change or related u…
-
CLINICAL_TRIALS research · 2024-12-31Clinical Trial Update: Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE) [EARLY_Phase 1]
A Phase 1 early trial (SATFRE) evaluating sirolomus as an adjuvant treatment for focal refractory epilepsy is currently recruiting at Xuanwu…